# Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

> **NCT07594093** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 90 (estimated)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** REGN20934
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07594093
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-02-22
- **Final completion:** 2027-02-22
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07594093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07594093, "Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity". Retrieved via AI Analytics 2026-08-16 from https://api.ai-analytics.org/clinical/NCT07594093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*